Cancer clinical trials in the region Île-de-France

787 currently recruiting clinical trials
Region Île-de-France
Phase 1 / Phase 2 Lymphoma CLL & Richter's syndrome #NCT06564038 #2024-515034-33-00
Required histologic types
B cell lymphoma CLL (Chronic Lymphocytic Leukemia)
Required histologic sub types
Lymphocytic lymphoma
Required number of previous lines of therapy
1 2 3 or more
Required previous treatments
Targeted therapy
Excluded previous treatments
Systemic Treatment-Naive
4 recruiting sites
AstraZeneca
Phase 1 / Phase 2 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT05181735 #2021-000596-37
Required histologic types
Myelodysplastic syndromes (MDS)
Required histologic sub types
MDS de novo Secondary MDS
Required renal function statuses
> 60 ml/min 50-60 ml/min 30-50 ml/min
Required number of previous lines of therapy
1 2 3 or more
Required previous treatments
EPO / Growth factors
Required IPSS-R prognostic scores
Low Intermediate
Required IPSS-M prognostic scores
Low Moderately low
Excluded genetic anomalies
del(5q)
Excluded previous treatments
Systemic Treatment-Naive
29 recruiting sites
Groupe Francophone des Myélodysplasies
Phase 1 / Phase 2 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT05280509
Required histologic types
Myeloproliferative neoplasms (MPN)
Required histologic sub types
Primary myelofibrosis Secondary myelofibrosis
Required number of previous lines of therapy
1
Required previous treatments
Targeted therapy
Required DIPSS scores
Intermediate-1 Intermediate-2 High
Excluded previous treatments
Systemic Treatment-Naive
5 recruiting sites
Telios Pharma, Inc.
Phase 1 / Phase 2 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT05280509
Required histologic types
Myeloproliferative neoplasms (MPN)
Required histologic sub types
Primary myelofibrosis Secondary myelofibrosis
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Required DIPSS scores
Intermediate-1 Intermediate-2 High
Excluded previous treatments
Targeted therapy
5 recruiting sites
Telios Pharma, Inc.
Phase 1 / Phase 2 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT05601726
Required histologic types
Myelodysplastic syndromes (MDS)
Required histologic sub types
MDS de novo Secondary MDS
Required number of previous lines of therapy
1 2 3 or more
Required IPSS-R prognostic scores
High Very high
Excluded previous treatments
Systemic Treatment-Naive
3 recruiting sites
Advanced BioDesign
Phase 1 / Phase 2 Acute leukemia #NCT05601726
Required histologic types
Acute myeloid leukemia (AML)
Required number of previous lines of therapy
2 3 or more
Excluded previous treatments
Systemic Treatment-Naive
3 recruiting sites
Advanced BioDesign
Phase 1 / Phase 2 Acute leukemia #NCT04771130 #2021-003285-12
Required histologic types
Acute myeloid leukemia (AML)
Required central nervous system lesions
None
Required renal function statuses
> 60 ml/min 50-60 ml/min
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded genetic anomalies
BCR-ABL
Excluded previous treatments
Targeted therapy
3 recruiting sites
BeOne Medecines
Phase 1 / Phase 2 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT04176198 #2022-502597-16-00
Required histologic types
Myeloproliferative neoplasms (MPN)
Required histologic sub types
Primary myelofibrosis Secondary myelofibrosis
Required number of previous lines of therapy
None
Required previous treatments
Targeted therapy
Required DIPSS scores
Intermediate-1 Intermediate-2 High
Required M-IPSS70+ v2.0 scores
Intermediate High
Required MYSEC-PM scores
Intermediate-1 Intermediate-2 High
8 recruiting sites
Sumitomo Pharma America, Inc.
Phase 1 / Phase 2 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT04176198 #2022-502597-16-00
Required histologic types
Myeloproliferative neoplasms (MPN)
Required histologic sub types
Primary myelofibrosis Secondary myelofibrosis
Required number of previous lines of therapy
1 2 3 or more
Required previous treatments
Targeted therapy
Required DIPSS scores
Intermediate-1 Intermediate-2 High
Required M-IPSS70+ v2.0 scores
Intermediate High
Required MYSEC-PM scores
Intermediate-1 Intermediate-2 High
Excluded previous treatments
Systemic Treatment-Naive
8 recruiting sites
Sumitomo Pharma America, Inc.
Phase 1 / Phase 2 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT04176198 #2022-502597-16-00
Required histologic types
Myeloproliferative neoplasms (MPN)
Required histologic sub types
Primary myelofibrosis Secondary myelofibrosis
Required number of previous lines of therapy
1 2 3 or more
Required previous treatments
Targeted therapy
Required DIPSS scores
Intermediate-1 Intermediate-2 High
Required M-IPSS70+ v2.0 scores
Intermediate High
Required MYSEC-PM scores
Intermediate-1 Intermediate-2 High
Excluded previous treatments
Systemic Treatment-Naive
8 recruiting sites
Sumitomo Pharma America, Inc.